Key result
The DD genotype of the alpha(2B)-adrenoceptor was associated with an increased risk of early-onset hypertension compared to the II genotype in nondiabetic subjects (OR 2.0; 95% CI 1.2-3.5).
Why the study?
Does the DD genotype of the alpha(2B)-adrenoceptor gene increase the risk of hypertension in a Swedish population?
Case-Control (n=1,760)
Does the DD genotype of the alpha(2B)-adrenoceptor gene increase the risk of hypertension in a Swedish population?
Answers are grounded in this paper and cite their sources.
The DD genotype of the alpha(2B)-adrenoceptor gene is associated with an increased risk of primary hypertension, particularly early-onset hypertension, in a Swedish population.
In a genome-wide scan in Scandinavians, we found suggestive linkage between early-onset primary hypertension and a region on chromosome 2. The alpha(2B)-adrenoceptor gene, a candidate gene within this region, harbors a functional insertion/deletion (I/D) polymorphism of three glutamate residues. The aim of this study was to investigate if the DD genotype is associated with hypertension in Swedes. We performed an association study between the I/D polymorphism of the alpha(2B)-adrenoceptor and hypertension in the Skaraborg population. The material consists of all known patients with primary hypertension in Skara (n=772 nondiabetic subjects; n=171 normoalbuminuric type 2 diabetic subjects) and 817 population control subjects. We first compared genotype frequencies between patients with early-onset hypertension (aged 50 years or younger at onset) and subjects with normotension (blood pressure <120/80 mm Hg). Thereafter, the polymorphism was tested for association with hypertension at the population level. When comparing patients with early-onset hypertension and normotensive subjects, the DD versus II genotype was associated with early-onset hypertension when diabetic subjects were excluded from the analysis (OR=2.0; 95% CI=1.2 to 3.5) or when they were not excluded (OR=1.8; 95% CI=1.0 to 3.1). At the population level, the DD versus II genotype was weakly associated with nondiabetic hypertension (OR=1.4; 95% CI=1.0 to 1.8). Our data suggest that carriers of the DD versus II genotype of the alpha(2B)-adrenoceptor are at increased risk for hypertension. The genotypic effect is most evident when comparing groups corresponding to the upper and lower tails of the blood pressure distribution in the population; however, in nondiabetic hypertensive subjects it is weakly detectable even at the population level.
No takes yet. Share an insight, caveat, or question.
Wowern et al. (2004) conducted a case-control in Primary hypertension (n=1,760). DD genotype of the alpha(2B)-adrenoceptor vs. II genotype was evaluated on Early-onset hypertension (excluding diabetic subjects) (OR 2.0, 95% CI 1.2 to 3.5). The DD genotype of the alpha(2B)-adrenoceptor was associated with an increased risk of early-onset hypertension compared to the II genotype in nondiabetic subjects (OR 2.0; 95% CI 1.2-3.5).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: